In:
Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 46, No. 9 ( 2021-9), p. 717-722
Abstract:
The aim of the present study was to obtain information about distribution, radiation dosimetry, toxicity, and pharmacokinetics of O -[ 18 F]fluoromethyl- d -tyrosine ( d - 18 F-FMT), an amino acid PET tracer, in patients with brain tumors. Patients and Methods A total of 6 healthy controls (age = 19–25 years, 3 males and 3 females) with brain PET images and radiation dosimetry and 12 patients (median age = 60 years, 6 males and 6 females) with primary (n = 5) or metastatic brain tumor (n = 7) were enrolled. We acquired 60-minute dynamic brain PET images after injecting 370 MBq of d - 18 F-FMT. Time-activity curves of d - 18 F-FMT uptake in normal brain versus brain tumors and tumor-to-background ratio were analyzed for each PET data set. Results Normal cerebral uptake of d - 18 F-FMT decreased from 0 to 5 minutes after injection, but gradually increased from 10 to 60 minutes. Tumoral uptake of d - 18 F-FMT reached a peak before 30 minutes. Tumor-to-background ratio peaked at less than 15 minutes for 8 patients and more than 15 minutes for 4 patients. The mean effective dose was calculated to be 13.2 μSv/MBq. Conclusions Using d - 18 F-FMT as a PET radiotracer is safe. It can distinguish brain tumor from surrounding normal brain tissues with a high contrast. Early-time PET images of brain tumors should be acquired because the tumor-to-background ratio tended to reach a peak within 15 minutes after injection.
Type of Medium:
Online Resource
ISSN:
1536-0229
,
0363-9762
DOI:
10.1097/RLU.0000000000003735
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
2045053-9
Permalink